Medicine News

Brand-Nu Laboratories Introduces Chlophedianol Hydrochloride
Wed, 14 July 2010
Brand-Nu Laboratories, a leading US-based high purity chemical manufacturer and distributor, has introduced Chlophedianol Hydrochloride, also known as Clofedanol Hydrochloride JP, to its product portfolio of active pharmaceutical ingredients (APIs). Chlophedianol Hydrochloride has been recognized as a possible replacement f ...
FDA Opens Two-Day Hearing To Examine Safety Of Diabetes Drug Avandia
Wed, 14 July 2010
The Fiscal Times: There will be more at stake than just one drug's future when the Food and Drug Administration opens a two-day hearing Tuesday on the safety of the diabetes drug Avandia...
High Resolution Photo Of A K Channel Improves Understanding Of The Effectiveness Of Drug ...
Wed, 14 July 2010
Using chemical labeling and mass spectrometry-based techniques, Mark Chance, PhD, director of the Case Western Reserve University School of Medicine Center for Proteomics and Bioinformatics and professor of physiology and biophysics; Sayan Gupta, PhD, instructor at the Case Center for Proteomics and Bioinformatics; and a res ...
FDA Approves Daytrana (methylphenidate Transdermal System) CII For The Treatment Of ADHD ...
Wed, 14 July 2010
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years...
Protalix BioTherapeutics Receives PDUFA Date For Taliglucerase Alfa
Wed, 14 July 2010
Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDU ...
Results From Study Of Vascular Calcification In Dialysis Patients Presented In Late-Brea ...
Wed, 14 July 2010
Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients...
ThromboGenics To Present Results Of Second Phase III Trial Of Microplasmin At The 28th A ...
Wed, 14 July 2010
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 2 ...
Pfizer Announces European Union Approval Of A New Form Of Lipitor (atorvastatin) For Use ...
Wed, 14 July 2010
Pfizer Inc...
Circadin Is Approved In The EU For Treatment Of Primary Insomnia In Patients Aged 55 Or ...
Wed, 14 July 2010
Neurim Pharmaceuticals confirmed that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over...
EntreMed's ENMD-2076 Demonstrates Significant Anti-Cancer Activity In Multiple Myeloma P ...
Wed, 14 July 2010
EntreMed, Inc. (Nasdaq: ENMDD), announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma (MM) cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's co ...

News

This section contains news related to the medicine industry.

Publishers of medicine related news can register for free on our website and add their medicine news to this website.

Our websites

Chemicals 1.com

GMP 1.com

Laboratory Supplies 1.com

Medical Products 1.com

Pharmaceuticals 1.com

Veterinary Products 1.com

More 1.com websites...

- About us
- About Medicines 1.com
- Email us
- Terms of use
- Using Medicines 1.com
- Register (free) / Join now
- Memberships
- How to buy/sell
- FAQ / Help

Medicine News - Medicines 1.com

Members in

Algeria
Angola
Benin
Botswana
Burundi
Cameroon
Cote d Ivoire
Djibouti
Ethiopia
Ghana
Guinea
Kenya
Liberia
Libyan Arab Jamahiriya
Malawi
Maldives
Mali
Mauritania
Mauritius
Morocco
Mozambique
Namibia
Niger
Nigeria
Senegal
Sierra Leone
Somalia
South Africa
Sudan
Tanzania, United Republic of
Togo
Tunisia
Uganda
Zaire
Zambia
Zimbabwe
Afghanistan
Bangladesh
Bermuda
Brunei Darussalam
Cambodia
China
Hong Kong
India
Indonesia
Japan
Kazakhstan
Kyrgyzstan
Malaysia
Mongolia
Myanmar
Nepal
Pakistan
Papua New Guinea
Philippines
Singapore
South Korea
Sri Lanka
Taiwan
Tajikistan
Thailand
Viet Nam
Albania
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Macedonia
Malta
Moldova,Republic of
Netherlands (Holland)
Norway
Poland
Portugal
Republic of Serbia
Romania
Russian Federation
San Marino
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
Ukraine
United Kingdom
Uzbekistan
Vatican City State (Holy See)
Yugoslavia
Bahrain
Egypt
Iran
Iraq
Israel
Jordan
Kuwait
Lebanon
Oman
Qatar
Saudi Arabia
Swaziland
Syrian Arab Republic
United Arab Emirates
Yemen
Antigua and Barbuda
Aruba
Bahamas
Barbados
Belize
Canada
Costa Rica
Cuba
Dominican Republic
El Salvador
Guatemala
Haiti
Honduras
Jamaica
Mexico
Netherlands Antilles
Nicaragua
Panama
Puerto Rico
Trinidad and Tobago
United States
Australia
Fiji
New Zealand
Saint Vincent and the Grenadines
Argentina
Bolivia
Brazil
Chile
Colombia
Ecuador
Paraguay
Peru
Suriname
Uruguay
Venezuela
American Samoa
Equatorial Guinea
Lesotho
Grenada

Medicine News

News

Advertisements